戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  barrier to resistance are used (lamivudine, adefovir).
2 turning to baseline after discontinuation of adefovir.
3 ht loss (P<.001) were associated with use of adefovir.
4  associated with resistance to foscarnet and adefovir.
5  confirmed using an OAT1-specific substrate, adefovir.
6 fovir may be a more promising alternative to adefovir.
7 with pegylated interferon alfa (Peg-IFN) and adefovir.
8 tions conveying resistance to lamivudine and adefovir.
9 n effort to improve the therapeutic index of adefovir, 1-aryl-1,3-propanyl prodrugs were synthesized
10 compensated CHB (group A) were randomized to adefovir 10 mg daily (n = 46) or placebo (n = 49) for 52
11 fference in de novo rates: LAM 8% (5 of 62), adefovir 15% (5 of 33), tenofovir 0% (0 of 3), entecavir
12 malization at follow-up after treatment with adefovir (2 RCTs; 600 patients) and HBeAg loss with lami
13 ted for 48 weeks with either PEG-alfa-2a and adefovir (ADV) or either drug alone in the Hep-Net-Inter
14 proved for HBV therapy, lamivudine (LVD) and adefovir (ADV), in several ways: ETV is >100-fold more p
15 thy caused by TFV and its more toxic analog, adefovir (ADV).
16 nged kidneys, compared to placebo treatment, adefovir, an EF inhibitor, decreased urine cAMP levels,
17                                Consequently, adefovir and cidofovir were approximately 500-fold and 4
18  (mOat1), originally identified as NKT (e.g. adefovir and cidofovir), two (ddC and ddI) manifested si
19 tical role in the organ-specific toxicity of adefovir and cidofovir, and indicates that CHOh OAT cell
20 pable of transporting the nucleotide analogs adefovir and cidofovir.
21 eir dose-limiting toxicity, particularly for adefovir and cidofovir.
22 ,3-propanyl prodrugs enhance the delivery of adefovir and its metabolites to the liver, with pradefov
23                             A combination of adefovir and lamivudine is preferred to adefovir monothe
24 ss-resistance profiles of these variants for adefovir and lamivudine, two other antiviral agents that
25 ost-liver transplantation (group B) received adefovir and lamivudine.
26 red with chemotherapeutic substrates such as adefovir and methotrexate.
27                                              Adefovir and tenofovir are associated with a dose-depend
28                      ATP-dependent uptake of adefovir and tenofovir but not cidofovir was observed on
29                  The ATP-dependent uptake of adefovir and tenofovir by MRP4 was not saturated at 1 mM
30                   The kidney accumulation of adefovir and tenofovir was significantly greater in Mrp4
31 P4 is involved in the luminal efflux of both adefovir and tenofovir, but it makes only a limited cont
32  nelfinavir together with delavirdine and/or adefovir and were followed for safety and antiretroviral
33 ucleoside or nucleotide analogs, lamivudine, adefovir, and entecavir, suppress HBV replication and ar
34 is is particularly true for tenofovir (TFV), adefovir, and other antiviral nucleosides that demonstra
35 e, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate antivirals.
36                                              Adefovir appears to be safe and effective as initial the
37 also showed activity against lamivudine- and adefovir-associated HBV mutants.
38 ays a role in the etiology of cidofovir- and adefovir-associated nephrotoxicity, we attempted to iden
39 resistant HBV to lamivudine, penciclovir, or adefovir but instead enhanced viral replication efficien
40                  The ATP-dependent uptake of adefovir by membrane vesicles expressing MRP4 was osmoti
41             Acyclic nucleotide phosphonates (adefovir, cidofovir, and tenofovir) are eliminated predo
42 the 50% effective concentration (EC(50)) for adefovir compared to the wild-type baseline isolate, whi
43 combined with nelfinavir and were lower with adefovir-containing regimens.
44                         Patients assigned to adefovir demonstrated a 0.4-log10 decline from baseline
45 nhance liver levels of the active metabolite adefovir diphosphate (ADV-DP) and/or decrease kidney exp
46 lovir-associated mutations were sensitive to adefovir diphosphate (ADVDP) in in vitro enzymatic assay
47                                              Adefovir diphosphate (PMEApp), the active cellular metab
48 s B virus (HBV), the inhibition constants of adefovir diphosphate and lamivudine triphosphate for wil
49 e location of catalytic site of CyaA and how adefovir diphosphate tightly binds CyaA.
50 with famciclovir, also remained sensitive to adefovir diphosphate with the inhibition constant increa
51 However, these mutants remained sensitive to adefovir diphosphate with the inhibition constants incre
52 (3TCTP), emtricitabine triphosphate (FTCTP), adefovir diphosphate, penciclovir triphosphate, and lobu
53  A crystal structure of CyaA-calmodulin with adefovir diphosphate, the metabolite of an approved anti
54 ques, only 1 of the 24 subjects who received adefovir dipivoxil (125 mg/day) developed any genotypic
55 eived 48 weeks of TDF 300 mg (HVL n = 82) or adefovir dipivoxil (ADV) 10 mg (HVL n = 47), followed by
56      Tenofovir disoproxil fumarate (TDF) and adefovir dipivoxil (ADV) are licensed for the treatment
57                                              Adefovir dipivoxil (ADV) has demonstrated clinical activ
58 he efficacy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children and adolescents wit
59 fter long-term (4 or 5 years) treatment with adefovir dipivoxil (ADV).
60 susceptibility to, and treatment failure of, adefovir dipivoxil (ADV).
61 n has been reported in patients treated with adefovir dipivoxil (ADV); however, its incidence and cli
62 e randomized 2:1 to receive TDF (n = 426) or adefovir dipivoxil (ADV; n = 215) for 48 weeks.
63  to receive either a single 120-mg/d dose of adefovir dipivoxil (n = 219) or an indistinguishable pla
64 f lamivudine-resistant HBV were treated with adefovir dipivoxil 10 mg once daily.
65 treatment with lamivudine were randomized to adefovir dipivoxil 10 mg, lamivudine 100 mg, or addition
66                         Forty-eight weeks of adefovir dipivoxil 10-mg therapy resulted in potent redu
67                        Antiviral efficacy of adefovir dipivoxil 10-mg therapy was examined with respe
68                                              Adefovir dipivoxil [9-(2-(bispivaloyloxymethyl)phosphony
69 is study assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivud
70 ith compensated liver disease, indicate that adefovir dipivoxil alone or in combination with ongoing
71            This study provides evidence that adefovir dipivoxil can be an effective treatment for lam
72  received placebo or one of three dosages of adefovir dipivoxil daily for 14 days.
73                     After 14 days of dosing, adefovir dipivoxil demonstrated anti-HIV activity and wa
74 s enrolled in a phase I/II clinical trial of adefovir dipivoxil demonstrated that the K70E RT mutatio
75 B-infected patients treated daily with 30 mg adefovir dipivoxil for 12 weeks displayed a median 4.1-l
76 % of patients who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resis
77 mivudine, adefovir dipivoxil/lamivudine, and adefovir dipivoxil groups, respectively.
78                                              Adefovir dipivoxil has a superior first line resistance
79               The patients were treated with adefovir dipivoxil in a dose of 5 to 30 mg daily.
80 ment-related adverse effects associated with adefovir dipivoxil in this setting were primarily mild t
81                                              Adefovir dipivoxil is a clinically approved drug that ca
82                                              Adefovir dipivoxil is a novel nucleotide analogue with s
83                                              Adefovir dipivoxil is a nucleotide analog that has demon
84                                              Adefovir dipivoxil is a promising new treatment for lami
85 /mL in the adefovir dipivoxil/lamivudine and adefovir dipivoxil monotherapy groups, respectively (P <
86       To evaluate the safety and efficacy of adefovir dipivoxil monotherapy, a randomized, double-bli
87                     Three patients receiving adefovir dipivoxil or adefovir dipivoxil/lamivudine and
88  randomly assigned in a 2:1 ratio to receive adefovir dipivoxil or placebo as a once-daily oral dose
89                                              Adefovir dipivoxil possesses potent in vitro and in vivo
90                   In conclusion, 48 weeks of adefovir dipivoxil resulted in significant improvements
91 1 RNA levels were significantly greater with adefovir dipivoxil than with placebo.
92                         Forty-eight weeks of adefovir dipivoxil therapy resulted in significant decre
93 anscriptase (RT) potentially attributable to adefovir dipivoxil therapy.
94 vudine resistance mutations may benefit from adefovir dipivoxil therapy.
95  evaluated the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with ch
96                              The addition of adefovir dipivoxil to lamivudine in patients with CHB wi
97 xil 10 mg, lamivudine 100 mg, or addition of adefovir dipivoxil to ongoing lamivudine daily.
98        In a phase II study of 6-12 months of adefovir dipivoxil treatment in human immunodeficiency v
99                                              Adefovir dipivoxil was determined to be safe and well-to
100                                              Adefovir dipivoxil was safe and effective for treatment-
101               Hepatitis B immunoglobulin and adefovir dipivoxil were initiated.
102                           We have found that adefovir dipivoxil, a drug approved to treat chronic inf
103                                              Adefovir dipivoxil, a marketed drug for the treatment of
104                                              Adefovir dipivoxil, a prototype phosphonate analog, has
105 placebo-controlled, dose-escalation study of adefovir dipivoxil, an oral prodrug of adefovir, was con
106  (PMEApp), the active cellular metabolite of adefovir dipivoxil, inhibits the adenylyl cyclase activi
107 d adults evaluated once-daily treatment with adefovir dipivoxil, lamivudine, didanosine, and efaviren
108 ipients of adefovir dipivoxil/lamivudine and adefovir dipivoxil, respectively, compared with 1 of 19
109 ts from 2 multinational phase III studies of adefovir dipivoxil.
110 on with amprenavir, abacavir, efavirenz, and adefovir dipivoxil.
111 r 6 weeks, followed by 6 weeks of open-label adefovir dipivoxil.
112 ne offer greater potency than lamivudine and adefovir dipivoxil.
113 d improvement in the liver/kidney ratio over adefovir dipivoxil.
114 ith -2.45 and -2.46 log(10) copies/mL in the adefovir dipivoxil/lamivudine and adefovir dipivoxil mon
115  of 19 (53%) and 9 of 18 (47%) recipients of adefovir dipivoxil/lamivudine and adefovir dipivoxil, re
116 ree patients receiving adefovir dipivoxil or adefovir dipivoxil/lamivudine and none receiving lamivud
117 d -4.04 log(10) copies/mL in the lamivudine, adefovir dipivoxil/lamivudine, and adefovir dipivoxil gr
118 el were seen by 4 weeks in all recipients of adefovir dipivoxil; DAVG(16) was -0.07 in the lamivudine
119 reated with pegylated interferon alfa-2a and adefovir for 48 weeks.
120 d a greater virologic response rate than did adefovir groups (40% vs. 18%; P=.002).
121 r between pooled delavirdine and delavirdine/adefovir groups (40% vs. 33%; P=.42).
122                                              Adefovir had a higher rate of de novo infections numeric
123 s with mutations resistant to lamivudine and adefovir have marked reduction in sensitivity to combina
124 ss the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected
125 tribute to the accumulation of cidofovir and adefovir in renal proximal tubules and, thus, play an ac
126 ction of mono- and diphosphorylated forms of adefovir in the kidney between wild-type and Mrp4 knocko
127 on demonstrated their full susceptibility to adefovir in vitro, and HBV with the rtI233V mutation dev
128 vir, lobucavir, and penciclovir in vitro and adefovir in vivo.
129 drugs (zidovudine, stavudine, tenofovir, and adefovir) increased when M184V was present, whereas susc
130                         To determine whether adefovir is active against lamivudine-resistant hepatiti
131                                 In contrast, adefovir is safe and has lower viral resistance but is m
132   The affinity of hOAT1 toward cidofovir and adefovir (K(m) = 46 and 30 microM, respectively) was 5-
133 ressed hOATI mediated efficient transport of adefovir (Km, = 23.8 tLM, V, a,, = 46.0 pmol/106 cells m
134 i-drug resistant HBV mutations to lamivudine+adefovir, lamivudine+hepatitis B immunoglobulin (HBIG),
135       Once-daily quadruple-drug therapy with adefovir, lamivudine, didanosine, and efavirenz provides
136  observed susceptibility of these mutants to adefovir, lobucavir, and penciclovir in vitro and adefov
137  was unsuccessfully treated with interferon, adefovir monotherapy and adefovir plus entecavir combina
138 n of adefovir and lamivudine is preferred to adefovir monotherapy for lamivudine-refractory hepatitis
139                       Neither lamivudine nor adefovir monotherapy is cost-effective in chronic HBV in
140                      Both the lamivudine and adefovir monotherapy strategies were more expensive yet
141 n monotherapy, 3) lamivudine monotherapy, 4) adefovir monotherapy, or 5) lamivudine with crossover to
142 ntly associated with response to Peg-IFN and adefovir (odds ratio, 0.44; P = .019).
143 hts the impact of exposure to lamivudine and adefovir on development of drug resistance and cross-res
144 However, a hybrid salvage strategy reserving adefovir only for lamivudine-associated viral resistance
145 rom patients who had developed resistance to adefovir or lamivudine, as demonstrated by development o
146 ir or nelfinavir, together with delavirdine, adefovir, or both, in indinavir-experienced persons.
147 or nelfinavir and, in addition, delavirdine, adefovir, or both.
148 mutations demonstrated anti-HIV effects with adefovir (P< or =.01 vs placebo group).
149 ed with interferon, adefovir monotherapy and adefovir plus entecavir combination.
150 )adenine (bis-POM PMEA)], an oral prodrug of adefovir (PMEA), is currently in phase III clinical test
151        De-novo combination of lamivudine and adefovir reduces the rate of antiviral resistance compar
152                However, 7 patients developed adefovir-related nephrotoxicity after >/=20 weeks of tre
153 eously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a
154                                           No adefovir resistance mutations were identified in patient
155  patients with chronic HBV infection in whom adefovir resistance occurred during treatment.
156  (in 2 samples) and S202G (in 1 sample), the adefovir-resistance mutation N236T (in 1 sample), and th
157  N236T (in 1 sample), and the lamivudine and adefovir-resistance mutations V173L, L180M, A181T, and M
158 ted excellent anti-HBV activity against both adefovir-resistant and lamivudine-resistant double (rtL1
159      We used UDPS to analyze the dynamics of adefovir-resistant HBV variants in patients with chronic
160 be added to lamivudine to reduce the risk of adefovir-resistant mutations; however, tenofovir may be
161  1 patient, nor were they associated with an adefovir-resistant phenotype in vitro.
162 t before treatment, and that the dynamics of adefovir-resistant populations are much more complex and
163                              The dynamics of adefovir-resistant variants were complex and differed am
164                                              Adefovir-resistant variants were partially inhibited by
165 cidofovir, oral and intraocular ganciclovir, adefovir, respiratory syncytial virus immune globulin, p
166                Compared with interferon, the adefovir salvage strategy cost an incremental 8446 dolla
167 with crossover to adefovir upon resistance ("adefovir salvage" strategy).
168 udine resistant hepatitis B virus infection, adefovir should be added to lamivudine to reduce the ris
169     The long-term studies of lamivudine (and adefovir) show a consistent reduction in the development
170 howed statistically significant increases in adefovir susceptibility of 3- to 4-fold (to near wild ty
171 ients showed no change or minor decreases in adefovir susceptibility, consistent with the durable ant
172 the licensing of lamivudine and subsequently adefovir, the treatment paradigm shifted from 4 to 6 mon
173          This study suggests that once-daily adefovir therapy reduces HIV RNA and is active against i
174 Rates of antiviral resistance are lower with adefovir therapy, approximately 30% at 5 years.
175 ing clinical adverse effect of cidofovir and adefovir, two potent antiviral therapeutics.
176 otherapy, or 5) lamivudine with crossover to adefovir upon resistance ("adefovir salvage" strategy).
177 n with two other drugs from the same family (adefovir, used to treat hepatitis B, and cidofovir, used
178 atment; this resolved without sequelae after adefovir was discontinued.
179                                              Adefovir was effective in suppressing lamivudine-resista
180                                   Open-label adefovir was offered after 24 weeks and was continued un
181 dy of adefovir dipivoxil, an oral prodrug of adefovir, was conducted in 36 human immunodeficiency vir
182  substitutions known to confer resistance to adefovir were detected at baseline in most patients.
183 nd cytarabine as well as the phosphonic acid adefovir were shown to cleave following exposure to live
184 sensitivity to combination of lamivudine and adefovir, whereas constructs with mutations resistant to

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top